Tyra Biosciences, Inc. (NASDAQ:TYRA) Holdings Cut by Ally Bridge Group NY LLC

Ally Bridge Group NY LLC lessened its stake in Tyra Biosciences, Inc. (NASDAQ:TYRA - Free Report) by 35.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 175,063 shares of the company's stock after selling 95,012 shares during the period. Tyra Biosciences comprises about 2.0% of Ally Bridge Group NY LLC's investment portfolio, making the stock its 24th largest position. Ally Bridge Group NY LLC owned approximately 0.35% of Tyra Biosciences worth $2,433,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in the stock. Boxer Capital Management LLC acquired a new stake in Tyra Biosciences during the fourth quarter valued at approximately $28,185,000. RA Capital Management L.P. raised its position in shares of Tyra Biosciences by 2.1% during the 4th quarter. RA Capital Management L.P. now owns 10,637,290 shares of the company's stock worth $147,858,000 after purchasing an additional 220,681 shares during the period. PDT Partners LLC acquired a new position in Tyra Biosciences during the 4th quarter valued at approximately $283,000. Nantahala Capital Management LLC acquired a new stake in Tyra Biosciences in the fourth quarter worth $1,390,000. Finally, Northern Trust Corp grew its position in Tyra Biosciences by 3.9% in the 4th quarter. Northern Trust Corp now owns 222,764 shares of the company's stock worth $3,096,000 after purchasing an additional 8,411 shares during the last quarter. 84.14% of the stock is currently owned by institutional investors.

Tyra Biosciences Price Performance

Shares of TYRA traded down $0.44 during trading hours on Wednesday, hitting $9.56. 346,678 shares of the company were exchanged, compared to its average volume of 256,789. The firm has a fifty day simple moving average of $9.73 and a 200-day simple moving average of $13.59. The company has a market capitalization of $507.54 million, a PE ratio of -6.00 and a beta of 1.17. Tyra Biosciences, Inc. has a one year low of $6.42 and a one year high of $29.60.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last announced its earnings results on Thursday, March 27th. The company reported ($0.43) EPS for the quarter, topping the consensus estimate of ($0.48) by $0.05. Sell-side analysts expect that Tyra Biosciences, Inc. will post -1.57 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on TYRA. HC Wainwright reaffirmed a "buy" rating and set a $30.00 target price on shares of Tyra Biosciences in a research note on Monday, March 31st. Wedbush restated an "outperform" rating and issued a $30.00 target price on shares of Tyra Biosciences in a research report on Friday, March 28th. Finally, UBS Group assumed coverage on Tyra Biosciences in a research report on Tuesday, January 7th. They set a "buy" rating and a $28.00 price target on the stock. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $30.83.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.